Reneo Pharmaceuticals stockholders approval merger with OnKure

Reneo Pharmaceuticals “announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo’s stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from “Reneo Pharmaceuticals, Inc.” to “OnKure Therapeutics, Inc.” and trade on The Nasdaq Global Market under the ticker symbol “OKUR.” The combined company will be led by OnKure’s existing management team. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kalpha), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. In addition, Reneo also announced that it will effect a 1-for-10 reverse split of its common stock that is expected to be effective immediately prior to the closing of the merger.”